دورية أكاديمية
Immunotherapy at any line of treatment improves survival in patients with advanced metastatic non‐small cell lung cancer (NSCLC) compared with chemotherapy (Quijote‐CLICaP)
| العنوان: | Immunotherapy at any line of treatment improves survival in patients with advanced metastatic non‐small cell lung cancer (NSCLC) compared with chemotherapy (Quijote‐CLICaP) |
|---|---|
| المؤلفون: | Alejandro Ruiz‐Patiño, Oscar Arrieta, Andrés F. Cardona, Claudio Martín, Luis E. Raez, Zyanya L. Zatarain‐Barrón, Feliciano Barrón, Luisa Ricaurte, María A. Bravo‐Garzón, Luis Mas, Luis Corrales, Leonardo Rojas, Lorena Lupinacci, Florencia Perazzo, Carlos Bas, Omar Carranza, Carmen Puparelli, Manglio Rizzo, Rossana Ruiz, Christian Rolfo, Pilar Archila, July Rodríguez, Carolina Sotelo, Carlos Vargas, Hernán Carranza, Jorge Otero, Luis E. Pino, Carlos Ortíz, Paola Laguado, Rafael Rosell, on behalf of the CLICaP |
| المصدر: | Thoracic Cancer, Vol 11, Iss 2, Pp 353-361 (2020) |
| بيانات النشر: | Wiley, 2020. |
| سنة النشر: | 2020 |
| المجموعة: | LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
| مصطلحات موضوعية: | Adult, immunotherapy, lung neoplasms, neoplasms/drug therapy, programmed cell death 1 receptor/antagonists & inhibitors, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282 |
| الوصف: | Background To compare survival outcomes of patients with advanced or metastatic non‐small cell lung cancer (NSCLC) who received immunotherapy as first‐, second‐ or beyond line, versus matched patients receiving standard chemotherapy with special characterization of hyperprogressors. Methods A retrospective cohort study of 296 patients with unresectable/metastatic NSCLC treated with either, first‐, second‐, third‐ or fourth‐line of immunotherapy was conducted. A matched comparison with a historical cohort of first‐line chemotherapy and a random forest tree analysis to characterize hyperprogressors was conducted. Results Median age was 64 years (range 34–90), 40.2% of patients were female. A total of 91.2% of patients had an Eastern Cooperative Oncology Group (ECOG) performance score ≤ 1. Immunotherapy as first‐line was given to 39 patients (13.7%), second‐line to 140 (48.8%), and as third‐line and beyond to 108 (37.6%). Median overall survival was 12.7 months (95% CI 9.67–14 months) and progression‐free survival (PFS) of 4.27 months (95% CI 3.97–5.0). Factors associated with increased survival included treatment with immunotherapy as first‐line (P |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 1759-7714 1759-7706 |
| العلاقة: | https://doaj.org/toc/1759-7706Test; https://doaj.org/toc/1759-7714Test |
| DOI: | 10.1111/1759-7714.13272 |
| الوصول الحر: | https://doaj.org/article/6b5eafa8845147498983649ec3646492Test |
| رقم الانضمام: | edsdoj.6b5eafa8845147498983649ec3646492 |
| قاعدة البيانات: | Directory of Open Access Journals |
Full Text Finder | تدمد: | 17597714 17597706 |
|---|---|
| DOI: | 10.1111/1759-7714.13272 |